1. Home
  2. REF vs ABUS Comparison

REF vs ABUS Comparison

Compare REF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

N/A

Current Price

$13.44

Market Cap

904.5M

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.00

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REF
ABUS
Founded
N/A
2005
Country
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.5M
1.0B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
REF
ABUS
Price
$13.44
$5.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
465.2K
4.4M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.84
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
N/A
$5.96
Revenue Growth
N/A
128.21
52 Week Low
$12.83
$3.50
52 Week High
$17.26
$5.45

Technical Indicators

Market Signals
Indicator
REF
ABUS
Relative Strength Index (RSI) 41.99 51.42
Support Level $12.90 $4.99
Resistance Level $15.92 $5.06
Average True Range (ATR) 0.90 0.08
MACD 0.10 -0.03
Stochastic Oscillator 21.04 14.00

Price Performance

Historical Comparison
REF
ABUS

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: